AU4904101A - Method for relieving pain associated with an internal disease site - Google Patents
Method for relieving pain associated with an internal disease siteInfo
- Publication number
- AU4904101A AU4904101A AU49041/01A AU4904101A AU4904101A AU 4904101 A AU4904101 A AU 4904101A AU 49041/01 A AU49041/01 A AU 49041/01A AU 4904101 A AU4904101 A AU 4904101A AU 4904101 A AU4904101 A AU 4904101A
- Authority
- AU
- Australia
- Prior art keywords
- pain associated
- relieving pain
- disease site
- internal disease
- internal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45749899A | 1999-12-08 | 1999-12-08 | |
| US09457498 | 1999-12-08 | ||
| PCT/US2000/042661 WO2001047512A2 (en) | 1999-12-08 | 2000-12-06 | Method for relieving pain associated with an internal disease site |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4904101A true AU4904101A (en) | 2001-07-09 |
Family
ID=23816983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU49041/01A Abandoned AU4904101A (en) | 1999-12-08 | 2000-12-06 | Method for relieving pain associated with an internal disease site |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU4904101A (en) |
| WO (1) | WO2001047512A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003066040A1 (en) * | 2002-02-05 | 2003-08-14 | Ajinomoto Co.,Inc. | Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist |
| FR2902341B1 (en) | 2006-06-16 | 2011-02-25 | Scras | THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE |
| FR2910327B1 (en) | 2006-12-22 | 2013-04-26 | Scras | USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING PAIN INDUCED BY THERAPEUTIC TREATMENTS OF AIDS VIRUS. |
| FR2930447B1 (en) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN IN THE CASE OF DIABETIC NEUROPATHY |
| CA2924233C (en) | 2013-10-07 | 2018-10-23 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
| JP6188933B2 (en) | 2013-10-07 | 2017-08-30 | テイコク ファーマ ユーエスエー インコーポレーテッド | Methods and compositions for transdermal delivery of non-sedating amounts of dexmedetomidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US6063758A (en) * | 1997-07-09 | 2000-05-16 | Advanced Targeting Systems, Inc. | Substance P-Saporin (SP-SAP) conjugates and methods of use thereof |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US6284223B1 (en) * | 1998-10-15 | 2001-09-04 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
| US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
-
2000
- 2000-12-06 WO PCT/US2000/042661 patent/WO2001047512A2/en active Application Filing
- 2000-12-06 AU AU49041/01A patent/AU4904101A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001047512A2 (en) | 2001-07-05 |
| WO2001047512A3 (en) | 2002-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4775900A (en) | Muscle contraction assist device | |
| AU2577299A (en) | Implantable therapeutic device and method | |
| AUPQ867900A0 (en) | Medical injector system | |
| AU2429401A (en) | Implantable electro-acupuncture device | |
| AU2002234121A1 (en) | Drug management techniques for an implantable medical device | |
| AU1050401A (en) | Device for cardiac therapy | |
| AU2003259249A1 (en) | Pyridazinylpiperazine derivatives for treating pain | |
| AU7743800A (en) | Implantable medical device | |
| AU3187600A (en) | Implantable stroke preventing device | |
| AU2735200A (en) | Device and method for stimulating salivation | |
| AU4211899A (en) | Implantable tissue repair device | |
| AU7725700A (en) | Implantable stimulation device for snoring treatment | |
| AU2001289095A1 (en) | Internal swage fitting | |
| AU6520499A (en) | Post-operative therapeutic device for amputees | |
| AU2446601A (en) | Server-side caching engine | |
| AU7089400A (en) | Chemical injector for oil well treatment | |
| AU1564001A (en) | Method and arrangement relating to positioning | |
| AU2980900A (en) | Methods for human allografting | |
| AU3529600A (en) | Cold distillation method | |
| AU4904101A (en) | Method for relieving pain associated with an internal disease site | |
| AU7646400A (en) | Method for producing an elongated drug formulation | |
| AUPP870999A0 (en) | Method of treatment of equine disease | |
| AU2001286341A1 (en) | Therapeutic bio-energy unit | |
| AU2566201A (en) | Compounds and methods for the treatment of pain | |
| AU4800500A (en) | Method for treatment of lyme disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |